Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Head & Neck 1CNS 1Breast 1

Conditions

Brain Neoplasms 640Glioblastoma 573Glioma 407Neuroblastoma 174Neoplasms 125Astrocytoma 107Central Nervous System Neoplasms 105Medulloblastoma 89Breast Neoplasms 86Meningioma 85Carcinoma, Non-Small-Cell Lung 78Melanoma 76Lung Neoplasms 70Sarcoma 65Ependymoma 64Neurofibromatosis 1 62Recurrence 50Neoplasm Metastasis 48Oligodendroglioma 47Meningeal Carcinomatosis 47Osteosarcoma 46Diffuse Intrinsic Pontine Glioma 45Rhabdomyosarcoma 44Pheochromocytoma 44Paraganglioma 42Rhabdoid Tumor 41Gliosarcoma 40Pancreatic Neoplasms 39Sarcoma, Ewing 38Colorectal Neoplasms 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anophthalmia with pulmonary hypoplasia × CNS × 1 year × Clear all
NCT06458712 2026-05-27

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Duke Street Bio Ltd

Phase 1 Recruiting
180 enrolled
CNS

Kenny-Caffey syndrome, Type 1, Anophthalmia with pulmonary hypoplasia, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡